1. Effect of anesthetic strategies on distal stroke thrombectomy in the anterior and posterior cerebral artery.
- Author
-
Meyer L, Stracke CP, Broocks G, Wallocha M, Elsharkawy M, Sporns PB, Piechowiak EI, Kaesmacher J, Maegerlein C, Hernandez Petzsche MR, Zimmermann H, Naziri W, Abdullayev N, Kabbasch C, Behme D, Thormann M, Maus V, Fischer S, Möhlenbruch MA, Weyland CS, Langner S, Ernst M, Jamous A, Meila D, Miszczuk M, Siebert E, Lowens S, Krause LU, Yeo LL, Tan BYQ, Gopinathan A, Gory B, Galvan Fernandez J, Schüller Arteaga M, Navia P, Raz E, Shapiro M, Arnberg F, Zeleňák K, Martínez-Galdámez M, Alexandrou M, Kastrup A, Papanagiotou P, Dorn F, Kemmling A, Psychogios MN, Andersson T, Chapot R, Fiehler J, and Hanning U
- Subjects
- Humans, Female, Middle Aged, Aged, Aged, 80 and over, Male, Posterior Cerebral Artery, Treatment Outcome, Thrombectomy adverse effects, Thrombectomy methods, Retrospective Studies, Brain Ischemia, Stroke surgery, Anesthetics, Endovascular Procedures methods
- Abstract
Background: Numerous questions regarding procedural details of distal stroke thrombectomy remain unanswered. This study assesses the effect of anesthetic strategies on procedural, clinical and safety outcomes following thrombectomy for distal medium vessel occlusions (DMVOs)., Methods: Patients with isolated DMVO stroke from the TOPMOST registry were analyzed with regard to anesthetic strategies (ie, conscious sedation (CS), local (LA) or general anesthesia (GA)). Occlusions were in the P2/P3 or A2-A4 segments of the posterior and anterior cerebral arteries (PCA and ACA), respectively. The primary endpoint was the rate of complete reperfusion (modified Thrombolysis in Cerebral Infarction score 3) and the secondary endpoint was the rate of modified Rankin Scale score 0-1. Safety endpoints were the occurrence of symptomatic intracranial hemorrhage and mortality., Results: Overall, 233 patients were included. The median age was 75 years (range 64-82), 50.6% (n=118) were female, and the baseline National Institutes of Health Stroke Scale score was 8 (IQR 4-12). DMVOs were in the PCA in 59.7% (n=139) and in the ACA in 40.3% (n=94). Thrombectomy was performed under LA±CS (51.1%, n=119) and GA (48.9%, n=114). Complete reperfusion was reached in 73.9% (n=88) and 71.9% (n=82) in the LA±CS and GA groups, respectively (P=0.729). In subgroup analysis, thrombectomy for ACA DMVO favored GA over LA±CS (aOR 3.07, 95% CI 1.24 to 7.57, P=0.015). Rates of secondary and safety outcomes were similar in the LA±CS and GA groups., Conclusion: LA±CS compared with GA resulted in similar reperfusion rates after thrombectomy for DMVO stroke of the ACA and PCA. GA may facilitate achieving complete reperfusion in DMVO stroke of the ACA. Safety and functional long-term outcomes were comparable in both groups., Competing Interests: Competing interests: JF: Consulting fees from Cerenovus, Medtronic, Phenox, Penumbra, Roche, Tonbridge; participation on a Data Safety Monitoring Board of Stryker and Phenox; stock holdings for Tegus and Vastrax, Associate Editor for JNIS. RC: Consultant and/or proctor for BALT, Stryker, Microvention, Rapid Medical, Siemens Medical Systems. MM: Institutional grants: Balt, Medtronic, MicroVention, Stryker. AG: Proctor/consultant/speaker for Medtronic, Stryker and Penumbra. MM-G: Consultant for Medtronic, Stryker and Balt, Associate Editor for JNIS. FD: Grant from Cerenovus/ Johnson&Johnson, consulting fees from Cerus Endovascular, Balt, Cerenovus/Johnson&Johnson, honoraria for lectures Asahi, Cerenovus/Johnson&Johnson, Acandis, Stryker, Advisory Board Cerenovus Johnson&Johsno, Associate Editor for JNIS. JK: Grants from SAMW/Bangerter, grants from Swiss Stroke Society, and grants from Clinical Trial Unit Bern outside the submitted work. LLLY: Consultant for Stryker, SeeMode, and See-mode, Cerenovus honoraria, Jakarta Neuroupdate honorarium, Research Support from National Medical research Council (NMRC) Singapore and Ministry of Health (MOH). Stock holdings for Cereflo, SNVIS vice president. BT: Grants from ExxonMobil-NUS Research Fellowship for Clinicians. PN: Consultant/Proctor for Balt, Cerenovus, Medtronic, Penumbra, Stryker. AG: Honoraria for lectures from Stryker Neurovascular, Medtronic, Penumbra. BG: grants from the French Ministry of Health and is the primary investigator of the TITAN, DIRECT ANGIO, and IA-RESCUE trial; consulting fees from Air Liquide, MIVI, Medtronic, Microvention, and Penumbra. LM: Compensation as a speaker for Balt Prime. GB: Compensation as a speaker for Balt Prime., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF